Company Overview

Artelo Biosciences Overview

Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions.

Clinical Progress and Expansion

Artelo's First Clinical Study and FABP5 Inhibition

Artelo has been selected to deliver a company presentation at BIO-Europe 2026, showcasing its clinical progress and expanding potential of its novel FABP5 inhibitor platform. The presentation highlights results from the first clinical study of ART26.12 and demonstrates the potential of FABP5 inhibition across multiple indications.

Upcoming Presentation

Artelo's Debut at BIO-Europe 2026

Artelo will be presenting at 4:15pm CET on November 10th at BIO-Europe 2026, being held November 9-11, 2026, in Cologne, Germany. This will be Artelo's first company presentation at BIO-Europe.

Expansion of Partnering Opportunities

Advancing Discussions and Opportunities

BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo's growing portfolio. The award of the presentation comes at an important point in the advancement of Artelo's pipeline, following favorable clinical and nonclinical data reported across multiple programs this year.

About Artelo Biosciences

Company Focus

Artelo Biosciences is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions. The company's pipeline includes several programs targeting various indications, with a focus on FABP5 inhibition.